Literature DB >> 10458264

Increased HER2 with U.S. Food and Drug Administration-approved antibody.

P C Roche, J N Ingle.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1999        PMID： 10458264     DOI： 10.1200/JCO.1999.17.1.434

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  14 in total

Review 1.  New data on adjuvant therapy for breast cancer.

Authors:  A C Wolff; N E Davidson
Journal:  Curr Oncol Rep       Date:  1999-09       Impact factor: 5.075

2.  Concomitant oncoprotein detection with fluorescence in situ hybridization (CODFISH): a fluorescence-based assay enabling simultaneous visualization of gene amplification and encoded protein expression.

Authors:  R R Tubbs; J Pettay; P Roche; M H Stoler; R Jenkins; J Myles; T Grogan
Journal:  J Mol Diagn       Date:  2000-05       Impact factor: 5.568

3.  Gold-facilitated in situ hybridization: a bright-field autometallographic alternative to fluorescence in situ hybridization for detection of Her-2/neu gene amplification.

Authors:  Raymond Tubbs; James Pettay; Marek Skacel; Richard Powell; Mark Stoler; Patrick Roche; James Hainfeld
Journal:  Am J Pathol       Date:  2002-05       Impact factor: 4.307

4.  IHC for Her2 with CBE356 antibody is a more accurate predictor of Her2 gene amplification by FISH than HercepTest in breast carcinoma.

Authors:  R Ainsworth; J M S Bartlett; J J Going; E A Mallon; A Forsyth; J Richmond; W Angerson; A Watters; B Dunne
Journal:  J Clin Pathol       Date:  2005-10       Impact factor: 3.411

5.  Laboratory assessment of the status of Her-2/neu protein and oncogene in breast cancer specimens: comparison of immunohistochemistry assay with fluorescence in situ hybridisation assays.

Authors:  S Wang; M H Saboorian; E Frenkel; L Hynan; S T Gokaslan; R Ashfaq
Journal:  J Clin Pathol       Date:  2000-05       Impact factor: 3.411

6.  Optical fiber-based in vivo quantification of growth factor receptors.

Authors:  Thommey P Thomas; Yu-Chung Chang; Jing Yong Ye; Alina Kotlyar; Zhengyi Cao; Rameshwer Shukla; Suyang Qin; Theodore B Norris; James R Baker
Journal:  Cancer       Date:  2011-08-25       Impact factor: 6.860

7.  [HER2 ASCO guidelines. The answer to everything?].

Authors:  E Burandt; G Sauter
Journal:  Pathologe       Date:  2010-10       Impact factor: 1.011

8.  Clinical usefulness of human epidermal growth factor receptor-2 extracellular domain as a biomarker for monitoring cancer status and predicting the therapeutic efficacy in breast cancer.

Authors:  Keiichi Kontani; Noriyuki Kuroda; Shin-ichiro Hashimoto; Chisa Murazawa; Shoko Norimura; Hiroaki Tanaka; Masahiro Ohtani; Naomi Fujiwara-Honjo; Yoshio Kushida; Manabu Date; Reiji Haba; Hitoshi Houchi; Akira Yamauchi; Hiroyasu Yokomise
Journal:  Cancer Biol Ther       Date:  2012-10-31       Impact factor: 4.742

9.  Testing for HER2 in Breast Cancer: A Continuing Evolution.

Authors:  Sejal Shah; Beiyun Chen
Journal:  Patholog Res Int       Date:  2010-12-06

10.  HER-2/neu oncogene amplification by chromogenic in situ hybridization in 130 breast cancers using tissue microarray and clinical follow-up studies.

Authors:  Eundeok Chang; Anhi Lee; Eunjung Lee; Hekyung Lee; Okran Shin; Sejeong Oh; Changsuk Kang
Journal:  J Korean Med Sci       Date:  2004-06       Impact factor: 2.153
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.